D. Boral Capital to Join Influential IPO Seminar in Seoul
Seoul, Friday, 12 September 2025.
D. Boral Capital will participate in CBA’s Go IPO Nasdaq seminar in Seoul, connecting emerging enterprises with investors and highlighting their role in facilitating capital access for growth-focused companies.
Strategic Participation in a Pivotal Event
D. Boral Capital, a global investment bank that specializes in middle-market and emerging growth companies, has announced its participation in the Cross Border Associates (CBA)’s Go IPO Nasdaq Seminar 2025. This significant event is scheduled to take place on September 16, 2025, at the COEX South Conference Room in Seoul, South Korea. The seminar is designed to connect emerging enterprises with potential investors while providing crucial insights into the IPO process and current market conditions [1].
Key Figures and Presentations
Stephanie (Mengjie) Hu, Co-Head of Investment Banking and Head of Asia, along with David Lee, Head of Secondaries & Follow-on Investment Banking at D. Boral Capital, are slated to speak at the seminar. Their presentation, titled ‘Capital Raising Strategies in the Current U.S. Market’, will take place at 3:40 PM Korea Standard Time on the seminar day. This session aims to equip high-growth companies in Asia with actionable insights on navigating the capital raising process and engaging with global investors [1].
D. Boral Capital’s Ongoing Commitment
Founded in 2020, D. Boral Capital is headquartered in New York and has successfully aggregated approximately $35 billion in capital through roughly 350 transactions. Their participation in this seminar underscores their commitment to fostering investment opportunities across Asia and enhancing their role as facilitators of capital access for growth-oriented businesses. This aligns with their strategic efforts to broaden their impact in the Asian market [1].
Broader Market Engagement
Beyond the seminar, D. Boral Capital continues to be an influential player in the financial markets, providing stock recommendations and ratings for various companies. Recently, they reiterated buy ratings for companies such as OS Therapies (NYSE: OSTX) and Enlivex Therapeutics (NASDAQ: ENLV), reflecting their ongoing engagement in the capital markets [2]. Their involvement in the seminar complements their broader market activities, showcasing their expertise and strategic vision in the investment banking sector.